Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Leases: 2021-2024

Historic Current Leases for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Dec 2024 value amounting to $5.6 million.

  • 4D Molecular Therapeutics' Current Leases rose 11.86% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 11.86%. This contributed to the annual value of $5.6 million for FY2024, which is 79.01% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Current Leases stood at $5.6 million, which was up 79.01% from $3.1 million recorded in FY2023.
  • 4D Molecular Therapeutics' Current Leases' 5-year high stood at $5.6 million during FY2024, with a 5-year trough of $1.2 million in FY2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Current Leases value was $3.1 million (recorded in 2023), while the average stood at $3.8 million.
  • Data for 4D Molecular Therapeutics' Current Leases shows a peak YoY soared of 115.68% (in 2022) over the last 5 years.
  • Over the past 4 years, 4D Molecular Therapeutics' Current Leases (Yearly) stood at $1.2 million in 2021, then spiked by 115.68% to $2.7 million in 2022, then increased by 18.61% to $3.1 million in 2023, then surged by 79.01% to $5.6 million in 2024.